| Website | regadobiosciences... |
| Category | BioTech |
| Phone | 919-287-9428 |
| Employees | |
| Founded | 2001 |
| Description | Biopharma |
| TOTAL | $40M |
| VENTURE FUNDING TOTAL | $40M |
| Series D, 12/09 Edmond de Rothschild Venture Capital Domain Associates Quaker BioVentures The Aurora Funds Caxton Advantage Life Sciences Fund | $40M |
Regado Biosciences, Inc., a biopharmaceutical company, engages in the discovery and development of aptamer-based antidote-controlled therapeutics. It provides REG1 that is used in patients suffering from acute coronary syndrome who undergo coronary revascularization procedures, which include coronary artery bypass grafting and percutaneous coronary intervention. Regado Biosciences, Inc. was formerly known as Quartet Biosciences, Inc. The company was incorporated in 2001 and is based in Durham, North Carolina.
